Formulary Watch
Latest News
All News
Advertisement
The first smallpox treatment, being developed for the United States government in the case of a bioterrorism attack, could be available as early as August.
A combination cancer treatment has been expanded to include treating both melanoma and anaplastic thyroid cancer (ATC).
FDA is re-examining the safety of a breakthrough Parkinson’s disease drug after reports of hundreds of deaths.
After FDA approved the first epinephrine injection specifically for infants and toddlers last year, the drug is now on the market.
A new draft guidance document from FDA aims to help pharmaceutical manufacturers develop new medications to treat opioid use disorder.
FDA approved a new treatment for non-small cell lung cancer, as well as drugs to treat chronic immune thrombocytopenia and a rare form of childhood rickets.
FDA is permitting marketing of the first medical device that uses artificial intelligence to detect greater than a mild level of the eye disease diabetic retinopathy.
Advertisement
FDA approved a new indication for Exparel Bupivacaine Liposome injectable suspension (Exparel, Pacira) for use as a nerve block to produce post-surgical regional analgesia following shoulder surgery in adults.
After US Surgeon General Jerome M. Adams, MD, MPH, urged more Americans to carry naloxone to reverse opioid overdoses, organizations and medical experts praised the decision.
A new deal between pharma giants AbbVie and Samsung Bioepis is designed to postpone competition against a biosimilar to Humira until 2023.
FDA okayed the marketing of a new continuous glucose monitoring system for diabetics-the first to be used as part of an integrated system with other compatible medical devices and electronic interfaces.
FDA’s approval of a new combination treatment for patients with classical Hodgkin lymphoma (cHL) is the first new advanced treatment for the disease in 40 years
Due to problems with compounded medications- including the 2012 fungal meningitis outbreak that led to 64 deaths-FDA is releasing a draft guidance that will determine which bulk drug substances outsourcing facilities can use to compound drugs.
President Donald Trump was expected to announce a new plan to combat the opioid crisis, even as a recent study found that prescription opioids were not as effective as over-the-counter medications for pain management.
As FDA considers new guidelines on pharmaceutical product marketing, a new study found that pharma makers may not be following current FDA ad regulations.
Over the past few months, several new diabetes treatments have been approved by FDA. Here are the top 3 novel drugs for diabetes.
A new FDA-approved drug offers new hope for patients with multidrug-resistant HIV-1 infection.
FDA approved the first direct-to-consumer test for three specific BRCA1/BRCA2 breast cancer gene mutations.
During the worst flu season in years, FDA is warning consumers about fraudulent and counterfeit flu and antiviral products from online pharmacies.
In a rare move, pharmaceutical manufacturers voluntarily recalled their drug to treat multiple sclerosis after reports of serious brain inflammation in patients.
The first radioactive drug to treat a certain type of cancer is among the top 3 new drug approvals for cancer. Here are the other top cancer drug approvals so far in 2018.
FDA said the manufacturer of dietary supplements containing kratom, a natural opioid used to treat opioid use disorder, agreed to destroy the supplements, and is again warning the public about kratom.
FDA should provide better education about biosimilar drugs on the agency’s web site dedicated to biosimilars, a patient advocacy group said.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
National Alliance survey shows employers are leaving the ‘big 3’ for other PBMs
2
Novo Nordisk's ziltivekimab falls short to reduce cardiovascular events in phase 3 trial
3
7 takeaways from the MHE webinar on PBM reform and transparency
4
What employees may miss when they buy drugs directly online
5